- Home
- SRTS vs TLPH Comparison
SRTS vs TLPH Comparison
Compare SRTS & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | TLPH |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 64.7M |
| IPO Year | 2016 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SRTS | TLPH |
|---|---|---|
| Price | $4.78 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $8.00 | $6.00 |
| AVG Volume (30 Days) | 73.5K | ★ 503.3K |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,609,000.00 | $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.12 | $14,267.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.03 | $0.38 |
| 52 Week High | $9.08 | $1.57 |
Technical Indicators
Market Signals| Indicator | SRTS | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 74.72 | 41.52 |
| Support Level | $4.30 | $1.02 |
| Resistance Level | $4.64 | $1.29 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 95.08 | 12.89 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.